Compare TDOC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | PVLA |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2015 | 2013 |
| Metric | TDOC | PVLA |
|---|---|---|
| Price | $6.23 | $151.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 15 |
| Target Price | $7.56 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 3.1M | 160.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,406,840,000.00 | $42,810,000.00 |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.25 | $104,350.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 18.41 | ★ 65.28 |
| 52 Week Low | $4.40 | $56.55 |
| 52 Week High | $9.89 | $161.38 |
| Indicator | TDOC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 50.36 |
| Support Level | $6.18 | $145.91 |
| Resistance Level | $6.24 | $151.18 |
| Average True Range (ATR) | 0.24 | 5.61 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 29.45 | 51.04 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.